Bayer’s Pipeline Progress and Legal Crossroads: A Stock Poised for a Binary Catalyst

Bayer beats Q1 earnings estimates but stock slides as investors eye June Supreme Court decision on Roundup liability. FDA grants accelerated review to three drugs; new CFO appointed.

The gulf between Bayer’s operational performance and its stock price has rarely been wider. The pharmaceutical-to-agrochemical group delivered a first-quarter earnings beat that surprised even the most bullish analysts, yet the shares continue to drift lower under the weight of America’s highest court. At €35.09, the stock has slipped more than 7% since the start of the year and sits almost 30% below the February peak near €50, as investors fixate on a ruling that could reshape the entire Roundup litigation landscape.

A decision from the Supreme Court in Monsanto v. Durnell is expected before the current session ends in June, making it the first time in roughly two decades that the justices will test whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) pre-empts state-law warning claims about the herbicide’s labels. If the ruling favours Bayer, it could effectively halt the flood of Roundup lawsuits. So far the market has priced in no such relief; the shares have traded as low as €34.52, a level that pushed the year-to-date decline past 9% and left the stock well below its 50-day moving average of €38.50.

The judicial calendar is packed with other land mines and opportunities. On 4 June the deadline for objections to Bayer’s Roundup class-action settlement expired, and a final approval hearing is scheduled for July. The confluence of these dates explains why the company’s chief executive told the Wall Street Journal’s Global Food Forum that a spin-off of Monsanto is off the table, stressing instead deeper operational improvements and a multi?pronged strategy that combines settlement deals with state?level political back?up.

Operationally, the numbers are hard to ignore. Underlying earnings per share came in at €2.71 for the first quarter of 2026, nearly 19% ahead of the consensus estimate of €2.28. Currency?adjusted revenue rose 4.1% to €13.4 billion, while adjusted EBITDA climbed 9%. Management confirmed the full?year outlook. What should have been a catalyst for the equity, however, was drowned out by legal noise.

Advertisement

Keeping your own workplace compliant with health and safety law can feel just as complex as navigating regulatory frameworks. A free toolkit provides 41 ready-to-use risk assessment templates, checklists, and training materials that help you document hazards and protect your team. Download the free Risk Assessment Toolkit

Meanwhile, the pharma pipeline is producing its own quiet ammunition. The U.S. Food and Drug Administration has granted accelerated review status to three Bayer assets: the oral Factor XIa inhibitor Asundexian, the kidney disease drug Kerendia, and Sevabertinib for a specific form of lung cancer. None of those designations guarantees commercial success, but they signal the regulator’s belief in the science. Bayer is also investing in ophthalmology through the acquisition of Perfuse Therapeutics, a U.S. biopharma firm focused on retinal diseases.

The management suite has changed, too. Judith Hartmann took over as chief financial officer on 1 June, sending a message of tighter capital discipline and cleaner balance?sheet management at a company with a market capitalisation of roughly €34.5 billion. The new CFO cannot erase legal legacy costs overnight, but she can sharpen the allocation of resources.

Technicians see little reason to jump in. The stock trades 8.7% below its 50?day average and is sitting just under the 200?day line, a configuration that has already triggered selling by trend?following funds. The relative strength index (RSI) reads 37.1 in one calculation and 33.0 in another — deep into oversold territory rather than obvious reversal ground. Yet the risk profile is asymmetric. A negative ruling would increase pressure but is not existential, given Bayer’s layered legal defence and settlement provisions. A positive one could remove the central overhang.

Advertisement

Over 37,000 UK businesses already use a free Health & Safety Toolkit to stay on top of their compliance duties. It covers everything from fire safety and COSHH to first aid and manual handling, with practical checklists you can use immediately. Get the free Health & Safety Toolkit

For now, the next big price impulse will arrive not from Leverkusen but from Washington. With a decision due within weeks, investors are left to weigh an encouraging earnings beat, a revived pipeline, and a broken chart against a single court date that could change everything.